デフォルト表紙
市場調査レポート
商品コード
1497676

がんバイオマーカー市場:バイオマーカータイプ別、がんタイプ別、技術別、用途別、エンドユーザー別-2024~2030年の世界予測

Cancer Biomarkers Market by Biomarker Type (Genetic, Protein), Cancer Type (Blood Cancer, Breast Cancer, Colorectal Cancer), Technology, Application, End User - Global Forecast 2024-2030

出版日: | 発行: 360iResearch | ページ情報: 英文 197 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.10円
がんバイオマーカー市場:バイオマーカータイプ別、がんタイプ別、技術別、用途別、エンドユーザー別-2024~2030年の世界予測
出版日: 2024年06月05日
発行: 360iResearch
ページ情報: 英文 197 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

がんバイオマーカー市場規模は、2023年に283億1,000万米ドルと推定され、2024年には312億3,000万米ドルに達し、CAGR 10.71%で2030年には577億5,000万米ドルに達すると予測されます。

がんバイオマーカーは、血液や組織など体内の一部で測定できる物質やプロセスであり、体内のがんの存在を検出するのに役立ちます。タンパク質、遺伝子変異、あるいは身体ががんと闘っている可能性を示すその他の分子です。がんバイオマーカーの使用は、主にこれらの検査の精度とスピードを向上させる技術の進歩により拡大しています。さらに、個々の患者に合わせた治療を行い、治療成績を向上させる個別化医療に対する意識の高まりが、がんバイオマーカーの応用を拡大させています。しかし、検査における偽陽性または偽陰性は、誤った治療決定につながる可能性があり、市場成長の課題となる可能性があります。とはいえ、膵臓がんや卵巣がんなど、現在のところ早期発見が困難なタイプのがんに対するバイオマーカー開拓は、市場拡大の幅を広げる可能性があります。さらに、バイオマーカーをデジタル医療情報システムと統合することで、患者のモニタリングや継続的な治療調整が強化される可能性もあります。

主な市場の統計
基準年[2023] 283億1,000万米ドル
予測年[2024] 312億3,000万米ドル
予測年 [2030] 577億5,000万米ドル
CAGR(%) 10.71%

地域別インサイト

南北アメリカでは、強固なヘルスケアインフラとがん検診や早期発見に対する高い意識ががんバイオマーカーの需要を牽引しています。この地域、特に米国には、新しいバイオマーカーの開発・商品化に取り組む数多くの大手バイオテクノロジー企業やヘルスケア企業があります。このマーケットプレースは政府の支援策や研究開発への多額の投資によって大きな恩恵を受けています。EMEA(欧州・中東・アフリカ)地域も、西欧では確立されたヘルスケアシステムがあり、中東・アフリカ諸国ではがん研究に対する政府支援が増加していることから、がんバイオマーカーにとって重要な市場となっています。アジア太平洋地域は、医療費の増加とがん有病率の増加により、がんバイオマーカー分野で急速な成長を示しています。中国、日本、インドなどの国々はヘルスケアのインフラや研究に多額の投資を行っており、成長を促進しています。さらに、これらの経済圏では中流階級の人口が拡大しており、がんバイオマーカーを含む先進的なヘルスケアソリューションの導入に大きな機会をもたらしています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは、がんバイオマーカー市場におけるベンダーのポジショニングを評価する上で不可欠です。このマトリックスはベンダーの包括的な評価を提供し、事業戦略や製品満足度に関連する重要な指標を検証します。この詳細な評価により、ユーザーは自らの要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功のレベルを表す4つの象限、すなわちForefront(F)、Pathfinder(P)、Niche(N)、Vital(V)に分類されます。

市場シェア分析

市場シェア分析は、がんバイオマーカー市場におけるベンダーの現状について、洞察に満ちた詳細な評価を提供する包括的なツールです。ベンダーの貢献度を綿密に比較・分析することで、各ベンダーの業績や市場シェア争いの際に直面する課題について、より深い理解を得ることができます。これらの貢献には、全体的な収益、顧客ベース、その他の重要な指標が含まれます。さらに、この分析では、調査対象期間の累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合性に関する貴重な考察を提供しています。このような詳細な情報を得ることで、ベンダーは市場競争において優位に立つために、より多くの情報に基づいた意思決定を行い、効果的な戦略を考案することができます。

戦略分析と推奨

戦略分析は、世界マーケットで確固たる足場を築こうとする組織にとって不可欠です。企業は、がんバイオマーカー市場における現在の立ち位置を徹底的に評価することで、長期的な願望に沿った情報に基づいた意思決定を行うことができます。この重要な評価には、組織のリソース、能力、全体的なパフォーマンスを徹底的に分析し、中核となる強みと改善すべき領域を特定することが含まれます。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 人口におけるがん疾患の罹患率の増加
      • がんの早期発見に向けた取り組みと啓発キャンペーンの増加
      • ヘルスケアインフラとヘルスケア費の拡大
    • 抑制要因
      • 研究開発にかかるコストの高さ
    • 機会
      • 悪性肝がんの検出のためのより優れたバイオマーカーの出現
      • 肺がんの早期発見のための新たなバイオマーカーの導入に向けた活発な調査活動
    • 課題
      • 複雑かつ厳格な規制遵守
  • 市場セグメンテーション分析
    • バイオマーカーの種類:血液や組織に含まれるタンパク質を通じてがんの存在を検出するタンパク質バイオマーカーの有用性
    • 応用:患者の治療結果を改善するための早期発見のための診断におけるバイオマーカーの選好
  • 市場ディスラプション分析
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 価格分析
  • 技術分析
  • 特許分析
  • 貿易分析
  • 規制枠組みの分析

第6章 がんバイオマーカー市場バイオマーカーの種類別

  • 遺伝的
  • タンパク質

第7章 がんバイオマーカー市場がんの種類別

  • 血液がん
  • 乳がん
  • 大腸がん
  • 肺がん
  • 卵巣がん
  • 前立腺がん
  • 皮膚ガン
  • 胃がん

第8章 がんバイオマーカー市場:技術別

  • バイオインフォマティクス
  • 細胞遺伝学
  • イメージング技術
  • 免疫学的検査
  • オミックス技術

第9章 がんバイオマーカー市場:用途別

  • 診断
  • 医薬品の発見と開発
  • 予測
  • リスクアセスメント

第10章 がんバイオマーカー市場:エンドユーザー別

  • 学術・がん研究センター
  • 病院
  • 専門センター

第11章 南北アメリカのがんバイオマーカー市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第12章 アジア太平洋地域のがんバイオマーカー市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第13章 欧州・中東・アフリカのがんバイオマーカー市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第14章 競合情勢

  • 市場シェア分析2023
  • FPNVポジショニングマトリックス, 2023
  • 競合シナリオ分析
    • クロマコードとジョージア医科大学が戦略的提携し、NSCLC診断能力を強化
    • 次世代がん診断のためのXtalPiとCK Life SciencesのAI連携強化
    • がん治療の精度向上:FDAが腫瘍治療薬のコンパニオン診断検査を規制するパイロットプログラムを開始
  • 戦略分析と提言

第15章 競合ポートフォリオ

  • 主要企業プロファイル
  • 主要製品ポートフォリオ
図表

LIST OF FIGURES

  • FIGURE 1. CANCER BIOMARKERS MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER BIOMARKERS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CANCER BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. CANCER BIOMARKERS MARKET DYNAMICS
  • FIGURE 7. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 16. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. CANCER BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 26. CANCER BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CANCER BIOMARKERS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CANCER BIOMARKERS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL CANCER BIOMARKERS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY GENETIC, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY GENETIC, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PROTEIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PROTEIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BREAST CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY LUNG CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY SKIN CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY SKIN CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY STOMACH CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY STOMACH CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CYTOGENETICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CYTOGENETICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY IMAGING TECHNOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY IMAGING TECHNOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY OMICS TECHNOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY OMICS TECHNOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PROGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PROGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY ACADEMIC & CANCER RESEARCH CENTERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY ACADEMIC & CANCER RESEARCH CENTERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY SPECIALITY CENTERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY SPECIALITY CENTERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 61. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 62. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 63. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 64. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 65. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 66. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 67. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 68. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 69. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 70. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 71. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 72. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 73. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 74. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 75. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 76. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 77. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 78. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 79. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 80. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 81. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 82. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 83. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 84. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 85. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 86. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 87. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 88. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 89. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 90. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 91. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 92. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 93. CANADA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 94. CANADA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 95. CANADA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 96. CANADA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 97. CANADA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 98. CANADA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 99. CANADA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 100. CANADA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 101. CANADA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 102. CANADA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 103. MEXICO CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 104. MEXICO CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 105. MEXICO CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 106. MEXICO CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 107. MEXICO CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 108. MEXICO CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 109. MEXICO CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 110. MEXICO CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 111. MEXICO CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 112. MEXICO CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 113. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 114. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 115. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 116. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 117. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 118. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 119. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 120. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 121. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 122. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 123. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 124. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 137. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 138. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 139. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 140. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 141. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 142. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 143. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 144. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 145. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 146. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 147. CHINA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 148. CHINA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 149. CHINA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 150. CHINA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 151. CHINA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 152. CHINA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 153. CHINA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 154. CHINA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 155. CHINA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 156. CHINA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 157. INDIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. INDIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. INDIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 160. INDIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 161. INDIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 162. INDIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 163. INDIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 164. INDIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 165. INDIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 166. INDIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 167. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 168. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 169. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 170. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 171. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 172. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 173. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 174. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 175. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 176. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 177. JAPAN CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 178. JAPAN CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 179. JAPAN CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 180. JAPAN CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 181. JAPAN CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 182. JAPAN CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 183. JAPAN CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 184. JAPAN CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 185. JAPAN CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 186. JAPAN CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 187. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 188. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 189. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 190. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 191. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 192. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 193. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 194. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 195. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 196. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 197. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 198. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 199. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 200. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 201. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 202. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 203. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 204. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 205. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 206. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 207. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 208. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 209. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 210. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 211. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 212. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 213. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 214. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 215. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 216. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 217. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 218. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 219. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 220. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 221. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 222. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 223. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 224. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 225. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 226. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 227. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 228. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 229. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 230. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 231. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 232. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 233. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 234. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 235. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 236. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 237. THAILAND CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 238. THAILAND CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 239. THAILAND CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 240. THAILAND CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 241. THAILAND CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 242. THAILAND CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 243. THAILAND CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 244. THAILAND CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 245. THAILAND CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 246. THAILAND CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 247. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 248. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 249. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 250. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 251. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 252. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 253. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 254. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 255. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 256. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 269. DENMARK CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 270. DENMARK CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 271. DENMARK CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 272. DENMARK CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 273. DENMARK CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 274. DENMARK CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 275. DENMARK CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 276. DENMARK CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 277. DENMARK CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 278. DENMARK CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 279. EGYPT CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 280. EGYPT CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 281. EGYPT CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 282. EGYPT CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 283. EGYPT CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 284. EGYPT CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 285. EGYPT CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 286. EGYPT CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 287. EGYPT CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 288. EGYPT CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 289. FINLAND CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 290. FINLAND CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 291. FINLAND CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 292. FINLAND CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 293. FINLAND CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 294. FINLAND CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 295. FINLAND CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 296. FINLAND CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 297. FINLAND CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 298. FINLAND CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 299. FRANCE CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 300. FRANCE CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 301. FRANCE CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 302. FRANCE CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 303. FRANCE CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 304. FRANCE CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 305. FRANCE CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 306. FRANCE CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 307. FRANCE CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 308. FRANCE CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 309. GERMANY CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 310. GERMANY CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 311. GERMANY CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 312. GERMANY CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 313. GERMANY CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 314. GERMANY CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 315. GERMANY CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 316. GERMANY CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 317. GERMANY CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 318. GERMANY CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 319. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 320. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 321. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 322. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 323. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 324. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 325. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 326. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 327. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 328. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 329. ITALY CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 330. ITALY CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 331. ITALY CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 332. ITALY CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 333. ITALY CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 334. ITALY CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 335. ITALY CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 336. ITALY CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 337. ITALY CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 338. ITALY CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 339. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 340. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 341. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 342. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 343. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 344. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 345. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 346. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 347. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 348. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 349. NIGERIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2023 (USD MILLION)
  • TABLE 350. NIGERIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024-2030 (USD MILLION)
  • TABLE 351. NIGERIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 352. NIGERIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 353. NIGERIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 354. NIGERIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 355. NIGERIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 356. NIGERIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2024-2030 (USD M
目次
Product Code: MRR-437517DB6E4D

[197 Pages Report] The Cancer Biomarkers Market size was estimated at USD 28.31 billion in 2023 and expected to reach USD 31.23 billion in 2024, at a CAGR 10.71% to reach USD 57.75 billion by 2030.

Cancer biomarkers are substances or processes that can be measured in parts of the body, such as blood or tissue, and help to detect the presence of cancer in the body. They can be proteins, genetic mutations, or other molecules that indicate the body may be fighting cancer. The use of cancer biomarkers is expanding primarily due to advancements in technology, which improve the accuracy and speed of these tests. Moreover, growing awareness of personalized medicine, which tailors treatment to individual patients and improves outcomes, has increased the applications of cancer biomarkers. However, false positives or negatives in tests, which can lead to incorrect treatment decisions, may challenge the market growth. Nevertheless, developing biomarkers for types of cancers that are currently hard to detect early, such as pancreatic or ovarian cancer, may increase the scope of market expansion. Additionally, integrating biomarkers with digital health information systems could enhance patient monitoring and ongoing treatment adjustments.

KEY MARKET STATISTICS
Base Year [2023] USD 28.31 billion
Estimated Year [2024] USD 31.23 billion
Forecast Year [2030] USD 57.75 billion
CAGR (%) 10.71%

Regional Insights

In the Americas, robust healthcare infrastructure and a high level of awareness about cancer screening and early detection drive the demand for cancer biomarkers. The region, especially the United States, is also home to numerous leading biotechnology and healthcare companies engaged in developing and commercializing new biomarkers. This marketplace benefits significantly from supportive government initiatives and substantial investment in research and development. EMEA also presents a substantial market for cancer biomarkers, supported by well-established healthcare systems in Western Europe and increasing government support for cancer research across the Middle Eastern and African countries. The Asia Pacific region showcases rapid growth in the cancer biomarkers field due to rising healthcare spending and the increasing prevalence of cancer. Countries such as China, Japan, and India are investing heavily in healthcare infrastructure and research, facilitating growth. Additionally, the expanding middle-class populations in these economies present a significant opportunity for the adoption of advanced healthcare solutions, including cancer biomarkers.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Cancer Biomarkers Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Increasing prevalence of cancer disorders among population
      • Rising initiatives and awareness campaigns for early cancer detection
      • Growing healthcare infrastructure and healthcare spending
    • Market Restraints
      • High costs associated with research and development
    • Market Opportunities
      • Emergence of better biomarkers for detection of aggressive liver cancer
      • Robust research activities to introduce new biomarkers for early detection of lung cancer
    • Market Challenges
      • Complex and stringent regulatory compliances
  • Market Segmentation Analysis
    • Biomarker Type: Usability of protein biomarkers in detecting the presence of cancer through proteins found in blood or tissue
    • Application: Preferences for biomarkers in diagnostic for early-stage detection to improve treatment outcomes for patients
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Cancer Biomarkers Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Cancer Biomarkers Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Strategic Collaboration between ChromaCode and Medical College of Georgia to Enhance NSCLC Diagnostic Capabilities

ChromaCode, Inc. and the Department of Pathology at the Medical College of Georgia have announced a partnership aimed at evaluating the performance of ChromaCode's innovative HDPCR assay for non-small cell lung cancer (NSCLC). This assay, endorsed for its comprehensive coverage of clinically relevant variants by the National Comprehensive Cancer Network, delivers rapid results with a 4-hour workflow and utilizes cloud-based analytics for quick interpretation. [Published On: 2024-03-20]

Enhanced AI Collaboration Between XtalPi and CK Life Sciences for Next-Generation Cancer Diagnostics

China-based XtalPi and CK Life Sciences are intensifying their joint efforts to utilize artificial intelligence (AI) to develop miRNA-based molecular diagnostic models tailored for postoperative cancer care. This collaboration aims to refine prognostic risk predictions by analyzing anonymized clinical data and biomarker information sourced from both cancer patients and healthy individuals within CK's extensive database. [Published On: 2023-11-06]

Enhancing Precision in Cancer Treatment: FDA Initiates Pilot Program to Regulate Companion Diagnostic Tests for Oncology Drugs

The U.S. Food and Drug Administration (FDA) has introduced a pivotal pilot program focused on refining the integration of specific oncology drugs with their corresponding in-vitro diagnostic tests. This initiative primarily addresses the critical use of laboratory-developed tests (LDTs), which have yet to undergo the FDA's extensive review for safety or effectiveness. The program aims to establish and make public the minimum performance characteristics necessary for diagnostic tests utilized in clinical trials. [Published On: 2023-06-21]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Cancer Biomarkers Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Cancer Biomarkers Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories Inc., Agilent Technologies, Inc., ASURAGEN, INC., Bio-Rad Laboratories, Inc., bioMerieux SA, Bristol-Myers Squibb Company, Bruker Corporation, Charles River Laboratories International, Inc., Enzo Biochem, Inc., Epigenomics AG, Eurofins Scientific SE, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., GE HealthCare Technologies Inc., Hologic, Inc., Illumina, Inc., Merck KGaA, Myriad Genetics, Inc., PerkinElmer, Inc., Pfizer Inc., QIAGEN N.V, Quest Diagnostics Incorporated, Siemens Healthcare GmbH, Sysmex Corporation, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Cancer Biomarkers Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Biomarker Type
    • Genetic
    • Protein
  • Cancer Type
    • Blood Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Lung Cancer
    • Ovarian Cancer
    • Prostate Cancer
    • Skin Cancer
    • Stomach Cancer
  • Technology
    • Bioinformatics
    • Cytogenetics
    • Imaging Technology
    • Immunoassays
    • OMICS Technology
  • Application
    • Diagnostics
    • Drug Discovery & Development
    • Prognostics
    • Risk Assessment
  • End User
    • Academic & Cancer Research Centers
    • Hospitals
    • Speciality Centers
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cancer disorders among population
      • 5.1.1.2. Rising initiatives and awareness campaigns for early cancer detection
      • 5.1.1.3. Growing healthcare infrastructure and healthcare spending
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with research and development
    • 5.1.3. Opportunities
      • 5.1.3.1. Emergence of better biomarkers for detection of aggressive liver cancer
      • 5.1.3.2. Robust research activities to introduce new biomarkers for early detection of lung cancer
    • 5.1.4. Challenges
      • 5.1.4.1. Complex and stringent regulatory compliances
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Biomarker Type: Usability of protein biomarkers in detecting the presence of cancer through proteins found in blood or tissue
    • 5.2.2. Application: Preferences for biomarkers in diagnostic for early-stage detection to improve treatment outcomes for patients
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Cancer Biomarkers Market, by Biomarker Type

  • 6.1. Introduction
  • 6.2. Genetic
  • 6.3. Protein

7. Cancer Biomarkers Market, by Cancer Type

  • 7.1. Introduction
  • 7.2. Blood Cancer
  • 7.3. Breast Cancer
  • 7.4. Colorectal Cancer
  • 7.5. Lung Cancer
  • 7.6. Ovarian Cancer
  • 7.7. Prostate Cancer
  • 7.8. Skin Cancer
  • 7.9. Stomach Cancer

8. Cancer Biomarkers Market, by Technology

  • 8.1. Introduction
  • 8.2. Bioinformatics
  • 8.3. Cytogenetics
  • 8.4. Imaging Technology
  • 8.5. Immunoassays
  • 8.6. OMICS Technology

9. Cancer Biomarkers Market, by Application

  • 9.1. Introduction
  • 9.2. Diagnostics
  • 9.3. Drug Discovery & Development
  • 9.4. Prognostics
  • 9.5. Risk Assessment

10. Cancer Biomarkers Market, by End User

  • 10.1. Introduction
  • 10.2. Academic & Cancer Research Centers
  • 10.3. Hospitals
  • 10.4. Speciality Centers

11. Americas Cancer Biomarkers Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Cancer Biomarkers Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Cancer Biomarkers Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Strategic Collaboration between ChromaCode and Medical College of Georgia to Enhance NSCLC Diagnostic Capabilities
    • 14.3.2. Enhanced AI Collaboration Between XtalPi and CK Life Sciences for Next-Generation Cancer Diagnostics
    • 14.3.3. Enhancing Precision in Cancer Treatment: FDA Initiates Pilot Program to Regulate Companion Diagnostic Tests for Oncology Drugs
  • 14.4. Strategy Analysis & Recommendation

15. Competitive Portfolio

  • 15.1. Key Company Profiles
  • 15.2. Key Product Portfolio